This Christmas season, we reflect on Jesus’ entering into this beautiful, yet broken world. God incarnate entered into human life where he would know both love and betrayal. Fellowship and forsakenness. Hospitality and hostility. He experienced the joy of eating and drinking with close friends. He celebrated at a wedding…
Entering Into the Full Human Experience
A single infusion of AstroRx, an off-the-shelf, investigational cell therapy for amyotrophic lateral sclerosis (ALS), safely and significantly slows disease progression in the first three months following treatment, according to updated data from an ongoing Phase 1/2 trial. These benefits waned after six months, indicating…
BrainStorm Cell Therapeutics has opened an expanded access program (EAP) in the U.S. to allow certain amyotrophic lateral sclerosis (ALS) patients to gain access to its investigational cell-based therapy NurOwn. EAPs, also known as compassionate use programs, are intended to make investigational therapies available outside of a clinical…
Every week, I receive an email from a friend that’s filled with cartoons, jokes, and quirky one-liners. And this time around, one quip struck me as feeling eerily true: “It feels weird being the same age as old people.” Why? Well, like most folks who share my age (I’m 69),…
Researchers at QurAlis have discovered a molecule with the potential to act as a treatment for amyotrophic lateral sclerosis (ALS), in addition to a new therapeutic target for the disease. The findings from both projects were presented at the 31st International Symposium on ALS/MND,…
A method that measures tiny amounts of aggregated TDP-43 protein in the cerebrospinal fluid may have the potential to detect amyotrophic lateral sclerosis (ALS) in the early stages of the disease, potentially before symptom onset, a study reports. The study,…
Target ALS is launching an expansive $15 million research initiative aimed at discovering biomarkers and developing new scientific resources for amyotrophic lateral sclerosis (ALS). The Target ALS Diagnosis Initiative, touted as the first of its kind, will create grants and scientific resources to identify needed biomarkers. Such indicators allow…
It’s time again to send our annual Christmas letter and picture card to our friends and family. Since my daughter could talk, I’ve kept a list of cute things the kids say throughout each year. I pick the best to include in our letter. When Sara was 2, we…
Cytokinetics is preparing a global Phase 3 trial that will enroll more than 500 people with early amyotrophic lateral sclerosis (ALS) to test its investigational therapy reldesemtiv in slowing progressive muscle weakness, the company announced. Details from the trial design were shared at the 31st International Symposium…
We Are All the Stuff of Legends
“All the world’s a stage, And all the men and women merely players; They have their exits and their entrances; And one man in his time plays many parts …” – William Shakespeare Some months back, I…
Recent Posts
- Actor Eric Dane honored for bringing visibility and hope to the ALS fight
- New ALS drug neflamapimod chosen for UK platform study
- Scientists find promising 3 drug combo for sporadic ALS using new models
- Small adjustments to a wheelchair can greatly improve comfort
- How ALS patients can show their stripes for Rare Disease Month